Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 2/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | HCK | P08631 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3441222 | 0.76 | ALDH1A1 (0.46) | TLR7TLR8LMNAPOLBHRH2 | |
| SCHEMBL5396347 | 0.70 | TLR7 (0.40) | TLR7ADORA2A | |
| SCHEMBL3441104 | 0.69 | MEN1 (0.50) | TLR7CYP2D6ADORA2A | |
| SCHEMBL3441040 | 0.68 | TLR7 (0.39) | TLR7TLR8ADORA2A | |
| SCHEMBL13533456 | 0.67 | TLR7 (0.65) | TLR7TLR8 | |
| SCHEMBL5398282 | 0.66 | ADORA2A (0.43) | TLR7CYP2D6CYP2C9CYP2C19HIF1A | |
| SCHEMBL5410118 | 0.65 | TLR7 (0.45) | TLR7LMNAADORA2A | |
| SCHEMBL3441048 | 0.65 | DHFR (0.46) | TLR7CYP2D6ADORA2A | |
| SCHEMBL1301722 | 0.65 | TLR7 (0.72) | TLR7TLR8 | |
| SCHEMBL5390832 | 0.64 | ILK (0.44) | TLR7TLR8LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238700-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1401837-B1 | PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040209899-A1 | A2B adenosine receptor antagonists | PALLE VENKATA (IN) | 2004-10-21 | — | — | US | disclosed |
| US-6770651-B2 | THERAPY FOR ASTHMA, DIARRHEA | PALLE VENKATA (US) | 2004-08-03 | — | — | US | disclosed |
| EP-1401837-A1 | PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030064999-A1 | A2B adenosine receptor antagonists | PALLE VENKATA (US) | 2003-04-03 | — | — | US | disclosed |
| WO-2003006465-A1 | PARTIAL AND FULL AGONIST OF A ADENOSINE RECEPTORS | CV THERAPEUTICS, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
| WO-2003002566-A1 | PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064999-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | TLR7 1635/4885PTPN1 4581/4885TLR8 1348/4885 |
| US-20040209899-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | TLR7 854/4885PTPN1 2484/4885TLR8 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.